ArticleOncogene2024

Fulvestrant and everolimus efficacy after CDK4/6 inhibitor: a prospective study with circulating tumor DNA analysis.

Antoine Vasseur et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.